Changing the Multibillion Dollar Game at CIRM: 'Inherent Limitations' Cited, Over-the-Transom Approach Questioned
A move to reshape how the $12 billion California stem cell and gene therapy program spends its money is “up and running” following a little-noticed meeting of a high-level committee at the agency.
In an unusual action last Friday afternoon, a member of the a…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.